Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00108576 · ClinicalTrials.gov registry record · Phase 3
Divalproex Sodium in the Treatment of PTSD (Post-Traumatic Stress Disorder)
A Phase 3 study of PTSD, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 101
- Enrollment target
- 1
- Study location
NCT00108576: Completed Phase 3 study of PTSD, sponsored by VA Office of Research and Development.
NCT00108576 is a Phase 3 study of PTSD that has completed, run by VA Office of Research and Development. The registered enrollment target is 101 participants, below the 301-participant average among 154 other PTSD trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00108576, a Phase 3 study of PTSD, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 101 participants
- Enrollment target
- 1
- Study location
Study Summary
The purposes of this study are: * To study the efficacy of divalproex in the treatment of PTSD; * To study the plasma GABA (gamma aminobutyric acid) levels before and after treatment with divalproex in PTSD.
Conditions Studied
Interventions
- OTHER placebo
- DRUG Divalproex
Study Locations (1)
Alabama
- Tuscaloosa VA Medical Center, Tuscaloosa, AL - Tuscaloosa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2003-10 |
| Est. Completion | 2005-09 |
| Phase | Phase 3 |
What the finished NCT00108576 record still lists
NCT00108576 is an interventional study that assigns participants to a tested intervention. The registered 101 participants enrollment target is mid-sized for trials with a published cap, below the 301-participant average among 154 other PTSD trials with a reported enrollment target (66% lower).
The record links to 1 condition, with PTSD appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00108576 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT00108576 about?
NCT00108576 is a clinical study titled "Divalproex Sodium in the Treatment of PTSD (Post-Traumatic Stress Disorder)". The purposes of this study are: * To study the efficacy of divalproex in the treatment of PTSD; * To study the plasma GABA (gamma aminobutyric acid) levels before and after treatment with divalproex in PTSD.
What is the current status of trial NCT00108576?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 101 participants. The study started on 2003-10. Estimated completion is 2005-09.
What conditions does trial NCT00108576 study?
This clinical trial studies the following conditions: PTSD.
What interventions are being tested in trial NCT00108576?
The interventions under investigation include: placebo (OTHER), Divalproex (DRUG).
Who is sponsoring clinical trial NCT00108576?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00108576 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PTSD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00108576's enrollment target sits among peer trials
101 61st of 154 higher than 94 of 154 other PTSD trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other PTSD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Repurposing Low-Dose Clonidine for PTSD in Veterans
RECRUITING · Phase 3
-
Individual PE vs Couples' CBT for Combat-Related Posttraumatic Stress Disorder
COMPLETED · Phase 3
-
Cooperative Studies Program #563 - Prazosin and Combat Trauma PTSD
COMPLETED · Phase 3
-
A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD
COMPLETED · Phase 3
-
Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial
RECRUITING · NA
-
Treatments for Insomnia in Veterans With PTSD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04033497 · 101 participants · NA
Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
- NCT05111574 · 101 participants · Phase 2
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
- NCT05984680 · 101 participants
COPD Care Pathway Among Patients With Cancer
- NCT06266299 · 101 participants · Phase 1
A Study of KK2269 in Adult Participants With Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia